Healthcare Demand Outstrips Supply in Noida; MOFSL Picks Medanta, Max
The Noida and Greater Noida healthcare market is rapidly transforming into one of North India’s most lucrative growth corridors. According to a recent report by Motilal Oswal Financial Services (MOFSL), a massive supply-demand gap is emerging as population growth and industrial expansion outpace the current availability of medical infrastructure.
A Growing Demographic Tailwind
The Noida-Greater Noida region is experiencing a structural shift from a satellite city to a self-sustaining urban hub. Over the last five years, the population has grown at a compound annual rate of 5.4%, reaching approximately 1.3 million. This growth is fueled by a robust expansion in IT services, manufacturing, electronics, data centers, and financial services.
This demographic surge is driving a high demand for specialized medical services, including cardiology, oncology, diabetes care, maternity, and pediatrics. Interestingly, the catchment area for these services is no longer limited to local residents; hospitals are seeing significant patient traffic from East Delhi and neighboring cities like Ghaziabad, Bulandshahr, and Aligarh.
Severe Under-penetration of Specialty Beds
Despite the increasing number of medical facilities, the region remains significantly under-penetrated. Industry estimates suggest there are only around 4,500 super-specialty beds currently serving the entire Noida, Greater Noida, and Western Uttar Pradesh belt.
There is a notable deficit in advanced healthcare services such as organ transplants, robotic-assisted procedures, and critical care. While infrastructure developments like improved metro connectivity, expressway networks, and the upcoming airport ecosystem are set to boost medical tourism, the competition for specialized medical talent remains a significant challenge, putting upward pressure on operational costs.
Top Picks: Medanta and Max Healthcare
Given the bullish outlook for the region, MOFSL has issued "Buy" recommendations for two major players poised to capture this market share.
Medanta (Target: Rs 1,490) Medanta is benefiting from high patient volumes and improving realizations. A key growth driver is its Noida facility, which is expected to achieve EBITDA breakeven in the second half of FY27. The company is also expanding into new markets including Indore, Varanasi, Guwahati, Mumbai, and South Delhi. MOFSL estimates a robust earnings CAGR of 28% over FY26-28, driven by the scaling of the Noida unit and an aggressive expansion pipeline.
Max Healthcare (Target: Rs 1,260) Max Healthcare operates a high-acuity network supported by strong diagnostics and homecare platforms. The company is focused on brownfield expansions and digital patient acquisition. While the Gurgaon greenfield project is expected to contribute from FY28, near-term growth will be driven by ramp-ups at Smart, Nanavati, and Mohali. MOFSL projects a consolidated PAT (Profit After Tax) CAGR of 20% over FY26-28.
Key Takeaways
- Supply Deficit: The Noida-Greater Noida region operates with only ~4,500 super-specialty beds, leaving a massive gap in advanced care like oncology and robotic surgery.
- Demographic Drivers: A 5.4% CAGR in population, coupled with industrial growth, is creating sustained demand for chronic and specialty disease management.
- Investment Outlook: MOFSL remains bullish on Medanta and Max Healthcare, citing capacity expansion and high occupancy rates as primary growth drivers.